114 related articles for article (PubMed ID: 32538593)
21. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
[TBL] [Abstract][Full Text] [Related]
22. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
[TBL] [Abstract][Full Text] [Related]
23. Factors That Affect Time to Switch From Warfarin to a Direct Oral Anticoagulant After Change in the Reimbursement Criteria in Patients With Atrial Fibrillation.
Park S; Je NK
J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):57-64. PubMed ID: 31405298
[TBL] [Abstract][Full Text] [Related]
24. Intracardiac Thrombus Following Rivaroxaban Treatment in a Patient with Atrial Fibrillation Associated with Rheumatic Heart Disease.
Ohara H; Yamamoto S; Nagano K; Hashikawa K
J Stroke Cerebrovasc Dis; 2019 Nov; 28(11):104325. PubMed ID: 31427189
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults.
Hasan SS; Kow CS; Curley LE; Baines DL; Babar ZU
Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):371-377. PubMed ID: 29741099
[TBL] [Abstract][Full Text] [Related]
26. The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation.
Fernández CS; Gullón A; Formiga F
J Comp Eff Res; 2020 May; 9(7):509-523. PubMed ID: 32329353
[TBL] [Abstract][Full Text] [Related]
27. Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
Huang HK; Liu PP; Hsu JY; Lin SM; Peng CC; Wang JH; Yeh JI; Loh CH
J Am Heart Assoc; 2020 Jan; 9(2):e013845. PubMed ID: 31918601
[TBL] [Abstract][Full Text] [Related]
28. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
Nicolau AM; Corbalan R; Nicolau JC; Ruff CT; Zierhut W; Kerschnitzki M; Duris T; Juul-Möller S; Voitk J; Trevisan M; Nordio F; Antman EM; Giugliano RP
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):167-175. PubMed ID: 31687762
[TBL] [Abstract][Full Text] [Related]
30. Management of Anticoagulant Treatment and Anticoagulation-Related Complications in Nonagenarians.
Giustozzi M; Castellucci LA; Barnes GD
Hamostaseologie; 2020 Aug; 40(3):292-300. PubMed ID: 32726824
[TBL] [Abstract][Full Text] [Related]
31. Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation.
Black-Maier E; Piccini JP; Granger CB
J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2968-2976. PubMed ID: 31520437
[TBL] [Abstract][Full Text] [Related]
32. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
[TBL] [Abstract][Full Text] [Related]
33. Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study.
Holbrook A; Morrow R; Lee AYY; Foster G; Pullenyegum E
J Popul Ther Clin Pharmacol; 2020 Apr; 27(2):e28-e44. PubMed ID: 32320170
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice: An Analysis of the ORBIT II Registry.
Sherwood MW; Piccini JP; Holmes DN; Pieper KS; Steinberg BA; Fonarow GC; Allen LA; Naccarelli GV; Kowey PR; Gersh BJ; Mahaffey KW; Singer DE; Ansell JE; Freeman JV; Chan PS; Reiffel JA; Blanco R; Peterson ED; Rao SV
Circ Cardiovasc Interv; 2020 May; 13(5):e008274. PubMed ID: 32408815
[TBL] [Abstract][Full Text] [Related]
35. Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies.
Liu X; Xu ZX; Yu P; Yuan P; Zhu WG
Cardiovasc Drugs Ther; 2020 Aug; 34(4):569-578. PubMed ID: 32297024
[TBL] [Abstract][Full Text] [Related]
36. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation.
Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P
Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378
[TBL] [Abstract][Full Text] [Related]
37. Trends in Prevalence of Non-Valvular Atrial Fibrillation and Anticoagulation Therapy in a Japanese Region - Analysis Using the National Health Insurance Database.
Narita N; Okumura K; Kinjo T; Mikami J; Tsushima K; Takahashi R; Noro M; Hashimoto A; Sasaki T; Takaki M; Ishidoya E; Narita Y; Imai H; Ono E; Tomita H
Circ J; 2020 Apr; 84(5):706-713. PubMed ID: 32213724
[TBL] [Abstract][Full Text] [Related]
38. Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.
Wu S; Xie S; Xu Y; Que D; Yau TO; Wang L; Huang Y
J Clin Nurs; 2019 May; 28(9-10):1839-1846. PubMed ID: 30667111
[TBL] [Abstract][Full Text] [Related]
39. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
Saliba W
Am J Cardiovasc Drugs; 2015 Oct; 15(5):323-35. PubMed ID: 26055615
[TBL] [Abstract][Full Text] [Related]
40. Optimizing the Safe Use of Direct Oral Anticoagulants in Older Patients: A Teachable Moment.
Sennesael AL; Dogné JM; Spinewine A
JAMA Intern Med; 2015 Oct; 175(10):1608-9. PubMed ID: 26237648
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
